While outcomes for breast cancer patients have steadily improved over the years, one particularly vexing type known as triple-negative breast cancer (TNBC) has continued to defy those rosy trends. One of the challenges in treating TNBC is that it […]
Here at Atomwise, we are really proud of the AtomNet® tool we’ve built to perform virtual screening of targets against billions of compounds to find promising candidates. This approach has already provided new leads for academic labs and drug […]
You probably hear about AI on a regular basis, but if you’re not a programmer steeped in machine learning algorithms, AI can seem like a mysterious black box.
Jeffrey MacKeigan is not your traditional academic scientist. After completing his postdoctoral fellowship, he spent two years at one of the largest pharmaceutical companies in the world. That gives him a unique perspective on how academic labs, […]
It’s not unusual for scientists to be discouraged by a lack of treatment options for their disease of interest. There is, however, a special kind of frustration for researchers who have clearly identified a promising biological target for treating […]
Atomwise is comprised of a world-class team of diverse disciplines internally referred to as "Atoms." In this Atom Spotlight, we sit down for a Q&A session with Mostafa Ahmed, PhD, a member of our Computer-Aided Drug Design (CADD) Modelers Team. […]
Drug discovery startup Atomwise, which joined the NVIDIA Inception virtual accelerator program in 2018, developed AtomNet, a convolutional neural network for small molecule drug discovery. The AtomNet AI technology can screen more than 16 billion […]
With the implementation of genomic technologies, medicine is becoming increasingly personalized thanks to new treatments that target important molecular targets. In the context of Parkinson's disease, there is an urgent need to identify molecular […]
Atomwise is comprised of a world-class team of diverse disciplines internally referred to as "Atoms." In this Atom Spotlight, we sit down for a Q&A session with Jeff Warrington, PhD, a member of our Computer-Aided Drug Design (CADD) Modelers Team. […]